SCHEMBL902729

SCHEMBL902729

CCOC(=O)c1cnn2c(O)c(Cc3ccc(Cl)cc3)c(C)nc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.55
KDM4E B2RXH2 8/20 0.55
HPGD P15428 6/20 0.55
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
CCNA2 P20248 1/20 0.52
CDK2 P24941 1/20 0.52
HSD17B10 Q99714 5/20 0.52
TSHR P16473 1/20 0.52
LMNA P02545 4/20 0.51
TP53 P04637 3/20 0.51
MAPT P10636 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15262398 0.91 HSD17B10 (0.61) ALDH1A1KDM4EHPGDCYP1A2CYP3A4
SCHEMBL4936715 0.90 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDCYP1A2CYP3A4
SCHEMBL22796687 0.90 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDCYP1A2CYP3A4
SCHEMBL15262374 0.90 CCNA2 (0.51) ALDH1A1KDM4EHPGDCYP1A2CYP3A4
SCHEMBL14033028 0.89 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDCCNA2CDK2
SCHEMBL15262169 0.89 KDM4E (0.48) ALDH1A1KDM4EHPGDCYP1A2CYP3A4
SCHEMBL22796561 0.88 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL15261996 0.88 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDCCNA2CDK2
SCHEMBL902125 0.88 HSD17B10 (0.65) ALDH1A1KDM4EHPGDCYP1A2CYP3A4
SCHEMBL15262467 0.87 CCNA2 (0.49) ALDH1A1KDM4EHPGDCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020252195-A1 TELOMERASE REVERSE TRANSCRIPTASE DEGRADERS AND METHODS OF USE THEREOF THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2020-12-17 WO disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 ALDH1A1 441/4885KDM4E 4265/4885HPGD 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.